ReviewInternational journal of hematology2002
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?
Review in International journal of hematology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Autologous hematopoietic stem cell transplantation for autoimmune diseases.Bone marrow transplantation · 2005Trial
- [Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2016Review
- Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas.Canadian journal of gastroenterology & hepatology · 2016Review
- Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature.Bone marrow transplantation · 2011Review
- Dendritic cells in hepatitis C infection: can they (help) win the battle?Journal of gastroenterology · 2011Review
- Autoimmune disease: is it a disorder of the microenvironment?Immunologic research · 2008Article
- Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.International journal of hematology · 2006Article
- Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.Annals of the rheumatic diseases · 2006Article
- T-cell depletion improves outcome after autologous stem cell transplant in patients with systemic lupus erythematosus (SLE).Bone marrow transplantation · 2005Article
- Cell therapy for autoimmune diseases: does it have a future?Annals of the rheumatic diseases · 2004Review
- Disappearance of diffuse calcinosis following autologous stem cell transplantation in a child with autoimmune disease.Bone marrow transplantation · 2004Article
- Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cells (HSCs) are the earliest cells of the immune system, giving rise to B and T lymphocytes, monocytes, tissue macrophages, and dendritic cells. In animal models, adoptive transfer of HSCs, depending on circumstances, may cause, prevent, or cure autoimmune diseases. Clinical trials have reported early remission of otherwise refractory autoimmune disorders after either autologous or allogeneic hematopoietic stem cell transplantation (HSCT). By percentage of transplantations performed, autoimmune diseases are the most rapidly expanding indication for stem cell transplantation. Although numerous editorials or commentaries have been previously published, no prior review has focused on the immunology of transplantation tolerance or development of phase 3 autoimmune HSCT trials. Results from current trials suggest that mobilization of HSCs, conditioning regimen, eligibility and exclusion criteria, toxicity, outcome, source of stem cells, and posttransplantation follow-up need to be disease specific. HSCT-induced remission of an autoimmune disease allows for a prospective analysis of events involved in immune tolerance not available in cross-sectional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.